BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22991415)

  • 1. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.
    Wermke M; Schmidt A; Middeke JM; Sockel K; von Bonin M; Schönefeldt C; Mair S; Plodeck V; Laniado M; Weiss G; Schetelig J; Ehninger G; Theurl I; Bornhäuser M; Platzbecker U
    Clin Cancer Res; 2012 Dec; 18(23):6460-8. PubMed ID: 22991415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
    Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of liver iron concentration by superconducting quantum interference device biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation.
    Jacobi N; Herich L
    Eur J Haematol; 2016 Oct; 97(4):336-41. PubMed ID: 26800433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.
    Wermke M; Eckoldt J; Götze KS; Klein SA; Bug G; de Wreede LC; Kramer M; Stölzel F; von Bonin M; Schetelig J; Laniado M; Plodeck V; Hofmann WK; Ehninger G; Bornhäuser M; Wolf D; Theurl I; Platzbecker U
    Lancet Haematol; 2018 May; 5(5):e201-e210. PubMed ID: 29628397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome.
    Tachibana T; Takasaki H; Tanaka M; Maruta A; Hyo R; Ishigatsubo Y; Kanamori H
    Bone Marrow Transplant; 2011 Jan; 46(1):150-1. PubMed ID: 20383206
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation.
    Virtanen JM; Itälä-Remes MA; Remes KJ; Vahlberg T; Saunavaara JP; Sinisalo M; Parkkola RK
    Eur J Haematol; 2013 Jul; 91(1):85-93. PubMed ID: 23586843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
    Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
    Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.
    Majhail NS; DeFor T; Lazarus HM; Burns LJ
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):790-4. PubMed ID: 18541198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
    Armand P; Kim HT; Rhodes J; Sainvil MM; Cutler C; Ho VT; Koreth J; Alyea EP; Hearsey D; Neufeld EJ; Fleming MD; Steen H; Anderson D; Kwong RY; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):852-60. PubMed ID: 20854920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
    Majhail NS; Lazarus HM; Burns LJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content.
    Trottier BJ; Burns LJ; DeFor TE; Cooley S; Majhail NS
    Blood; 2013 Aug; 122(9):1678-84. PubMed ID: 23777771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
    Scott BL; Storer BE; Greene JE; Hackman RC; Appelbaum FR; Deeg HJ
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):345-54. PubMed ID: 17317588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in allo-SCT of elderly patients with AML.
    Krauter J; Wagner K; Stadler M; Dammann E; Zucknick M; Eder M; Buchholz S; Mischak-Weissinger E; Hertenstein B; Ganser A
    Bone Marrow Transplant; 2011 Apr; 46(4):545-51. PubMed ID: 20548341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron overload in allogeneic hematopoietic stem cell transplant recipients.
    Ali S; Pimentel JD; Munoz J; Shah V; McKinnon R; Divine G; Janakiraman N
    Arch Pathol Lab Med; 2012 May; 136(5):532-8. PubMed ID: 22540302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.